Literature DB >> 29328495

Fucoidan downregulates insulin-like growth factor-I receptor levels in HT-29 human colon cancer cells.

In-Hye Kim1, Taek-Jeong Nam1.   

Abstract

Fucoidan, a sulfated polysaccharide present in brown seaweed, has demonstrated anticancer activity in lung, breast, liver and colon cells. The insulin-like growth factor (IGF) signaling pathway regulates growth in HT-29 cells through the insulin receptor substrate-1 (IRS-1)/phosphatidylinositol 3-kinase (PI3K)/protein kinase B (AKT) and Ras/Raf/extracellular signal-regulated kinase (ERK) pathways. The aim of the present study was to investigate whether fucoidan downregulates the IGF-IR signaling pathway in HT-29 human colon cancer cells. Fucoidan treatment (0-1,000 µg/ml) was administered for 24 h in HT-29 cells. First, we investigated IRS-1/PI3K/AKT pathway-related protein expression levels following treatment with fucoidan (0-500 µg/ml) using western blot analysis. Fucoidan significantly inhibited the expression of IGF-IR, PTEN, PI3K and AKT as well as their phosphorylated forms (p-IRS-1, p-PI3K and p-AKT). Next, we investigated the effects of fucoidan on Ras/Raf/ERK pathway‑related protein expression levels in HT-29 cells. Fucoidan significantly inhibited the expression of IGF-IR, Shc, Ras, SOS, Raf and MEK. HT-29 cells were then incubated in the presence of fucoidan (0 or 250 µg/ml), and IGF-I (10 nM) was added for 0 to 60 min. Immunoprecipitation (IP) experiments showed that fucoidan inhibited IGF-I-induced phosphorylation of IGF-IR, PI3K, Shc (IP, IGF-IR), and phosphorylated IRS-1 and PI3K (IP, IRS-1) compared to the control group. Western blot analysis showed that fucoidan inhibited the expression of IGF-I-induced p-IGF-IR/IGF-IR and p-AKT/AKT, but not p-ERK/ERK. In conclusion, the inhibition of cell viability by fucoidan in HT-29 cells may be due to the downregulation of IGF-IR signaling through the main IRS-1/PI3K/AKT pathway. Fucoidan also partially impacted Ras/Raf signaling in the Ras/Raf/ERK pathway. Therefore, we suggest that fucoidan may be a suitable candidate chemopreventive agent in HT-29 colon cancer cells.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29328495     DOI: 10.3892/or.2018.6193

Source DB:  PubMed          Journal:  Oncol Rep        ISSN: 1021-335X            Impact factor:   3.906


  7 in total

1.  The Natural Product Fucoidan Inhibits Proliferation and Induces Apoptosis of Human Ovarian Cancer Cells: Focus on the PI3K/Akt Signaling Pathway.

Authors:  Shuhan Liu; Jing Yang; Xudong Peng; Jingjing Li; Cunjing Zhu
Journal:  Cancer Manag Res       Date:  2020-07-23       Impact factor: 3.989

2.  Dichloromethane fractions of Calystegia soldanella induce S‑phase arrest and apoptosis in HT‑29 human colorectal cancer cells.

Authors:  In-Hye Kim; Taekil Eom; Joon-Young Park; Hyung-Joo Kim; Taek-Jeong Nam
Journal:  Mol Med Rep       Date:  2021-12-22       Impact factor: 2.952

Review 3.  Fucoidans and Bowel Health.

Authors:  Jin-Young Yang; Sun Young Lim
Journal:  Mar Drugs       Date:  2021-07-30       Impact factor: 5.118

Review 4.  The Insulin-like Growth Factor System and Colorectal Cancer.

Authors:  Nikola Gligorijević; Zorana Dobrijević; Miloš Šunderić; Dragana Robajac; Danilo Četić; Ana Penezić; Goran Miljuš; Olgica Nedić
Journal:  Life (Basel)       Date:  2022-08-20

Review 5.  Anti-colorectal cancer effects of seaweed-derived bioactive compounds.

Authors:  Yunhua Fu; Dong Xie; Yinghao Zhu; Xinyue Zhang; Hao Yue; Kai Zhu; Zifeng Pi; Yulin Dai
Journal:  Front Med (Lausanne)       Date:  2022-08-19

Review 6.  The Therapeutic Potential of the Anticancer Activity of Fucoidan: Current Advances and Hurdles.

Authors:  Jun-O Jin; Pallavi Singh Chauhan; Ananta Prasad Arukha; Vishal Chavda; Anuj Dubey; Dhananjay Yadav
Journal:  Mar Drugs       Date:  2021-05-10       Impact factor: 5.118

Review 7.  The anti-cancer effects of fucoidan: a review of both in vivo and in vitro investigations.

Authors:  Yuan Lin; Xingsi Qi; Hengjian Liu; Kuijin Xue; Shan Xu; Zibin Tian
Journal:  Cancer Cell Int       Date:  2020-05-07       Impact factor: 5.722

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.